- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
NATCO Pharma Gets USFDA EIR for Visakhapatnam Plant After 4 Observations, Classified VAI

Hyderabad: NATCO Pharma Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its finished dosage form (FDF) manufacturing facility in Parawada, Visakhapatnam, Andhra Pradesh, with the inspection classified as Voluntary Action Indicated (VAI).
In a regulatory disclosure, the Hyderabad-based pharmaceutical company informed that the USFDA had conducted an inspection of its FDF manufacturing plant from August 17 to August 21, 2026. At the conclusion of the inspection, the facility was issued four observations in Form 483.
The company has now received the EIR from the US drug regulator, confirming the classification of the inspection as VAI.
NATCO Pharma develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients (APIs) and crop protection products.
Headquartered in Hyderabad, the company is a research and development-oriented pharmaceutical manufacturer with a focus on oncology and targeted therapies in the domestic market, as well as limited-competition molecules in the US market.
Its manufacturing facilities have approvals from several leading regulatory authorities, including the USFDA, Brazil's ANVISA, Health Canada and the World Health Organization (WHO). The company caters to more than 50 global markets.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

